ALLMedicine™ Lipoprotein (a) Center
Research & Reviews 575 results
https://doi.org/10.1093/eurjpc/zwaa063
European Journal of Preventive Cardiology; Welsh P, Welsh C et. al.
Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...
https://doi.org/10.1177/2047487320905727
European Journal of Preventive Cardiology; Dal Pino B, Bigazzi F et. al.
Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853621
Metabolism: Clinical and Experimental; Ong KL, McClelland RL et. al.
Jan 9th, 2021 - Elevated plasma lipoprotein (a) [Lp(a)] and coronary artery calcification (CAC) are established cardiovascular risk factors that correlate with each other. We hypothesized that other cardiovascular risk factors could affect their relationship. We ...
https://doi.org/10.1002/jca.21872
Journal of Clinical Apheresis REFERENCES; Mickiewicz A, Marlega J et. al.
Jan 2nd, 2021 - Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in pat...
https://doi.org/10.1016/j.diabres.2020.108622
Diabetes Research and Clinical Practice; Jun JE, Kang H et. al.
Dec 14th, 2020 - Lipoprotein (a) [Lp(a)] has been considered a determinant of residual cardiovascular risk. We aimed to investigate associations between serum Lp(a) levels and carotid atherosclerosis. This cross-sectional study included 662 type 2 diabetic patient...
Clinicaltrials.gov 587 results
https://doi.org/10.1093/eurjpc/zwaa063
European Journal of Preventive Cardiology; Welsh P, Welsh C et. al.
Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...
https://doi.org/10.1177/2047487320905727
European Journal of Preventive Cardiology; Dal Pino B, Bigazzi F et. al.
Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7853621
Metabolism: Clinical and Experimental; Ong KL, McClelland RL et. al.
Jan 9th, 2021 - Elevated plasma lipoprotein (a) [Lp(a)] and coronary artery calcification (CAC) are established cardiovascular risk factors that correlate with each other. We hypothesized that other cardiovascular risk factors could affect their relationship. We ...
https://doi.org/10.1002/jca.21872
Journal of Clinical Apheresis REFERENCES; Mickiewicz A, Marlega J et. al.
Jan 2nd, 2021 - Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in pat...
https://doi.org/10.1016/j.diabres.2020.108622
Diabetes Research and Clinical Practice; Jun JE, Kang H et. al.
Dec 14th, 2020 - Lipoprotein (a) [Lp(a)] has been considered a determinant of residual cardiovascular risk. We aimed to investigate associations between serum Lp(a) levels and carotid atherosclerosis. This cross-sectional study included 662 type 2 diabetic patient...
News 9 results
https://www.reuters.com/article/us-novartis-ionis-pharma-licensing/novartis-aims-to-pump-up-cardio-business-with-ionis-deal-idUSKCN1QE0KT
Feb 25th, 2019 - ZURICH (Reuters) - Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto. FILE ...
https://www.mdedge.com/ccjm/article/96071/cardiology/niacins-effect-cardiovascular-risk-have-we-finally-learned-our-lesson?channel=194
Stephen J. Nicholls, MBBS, PhD
May 1st, 2014 - Randomized controlled trials have unequivocally shown that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of cardiovascular events. 1–3 Yet many patients still have heart attacks even though they are on.
https://www.medscape.com/viewarticle/778878
Feb 5th, 2013 - MONTREAL, Quebec — An international consortium has identified a variation in the gene coding for lipoprotein (a) (Lp[a]), which appears to be strongly associated with aortic-valve calcification [1]. People carrying this single nucleotide polymorph...
https://www.medscape.com/viewarticle/754584
Nov 30th, 2011 - December 1, 2011 (Houston, Texas) — Elevated levels of lipoprotein (a) [Lp(a)] are associated with cardiovascular events in African Americans, and the risk is comparable to that seen in whites, a new analysis of the Atherosclerosis Risk in Communi...
https://www.medscape.com/viewarticle/706265
Jul 20th, 2009 - July 21, 2009 (Cambridge, United Kingdom) — A new pooled analysis of 36 prospective studies shows there is a continuous association between blood concentration of lipoprotein (a)--Lp(a)--and the risk of MI and stroke [1]. Importantly, this associa...